Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Compass Therapeutics (CMPX), a Boston-based monoclonal antibody discovery and development company, has three clinical-stage programs with a fourth about to enter the clinic. Its lead DLL4xVEGF‑A bispecific, tovecimig, has secondary endpoint readouts for progression-free survival and overall survival expected at the end of Q1 2026, and a PD‑1/PD‑L1 bispecific reported three responses among the first 15 dose-escalation patients (including a first‑in‑human de minimis dose) and is moving into cohort expansions in triple‑negative breast cancer and non‑small cell lung cancer with readouts planned in H2 2026.

Analysis

Market structure: A positive Q1 2026 PFS/OS readout for CMPX's Tovecimig would directly benefit CMPX (CMPX), early bispecific developers and CROs supporting registrational trials; competitors with late-stage VEGF or DLL4 programs could lose pricing power. The 3/15 responses (20%) in the PD‑1/PD‑L1 bispecific dose escalation materially increases optionality — a successful cohort expansion in 2H/2026 would raise M&A and licensing value and lift implied vol across small‑cap biotech options, while a failure would widen credit spreads for similarly capital‑intensive small biotechs.

Risk assessment: Tail risks include a negative PFS/OS readout, class safety signal for DLL4 (vascular/hepatic toxicity), or acute cash‑runway dilution; any of these could knock CMPX >50% within days. Time horizons: expect idiosyncratic volatility immediate (days post‑news), decisive moves by end‑Q1/2026 (weeks → months) and definitive capital/partnering outcomes over 12–24 months. Hidden dependencies include comparator choice and maturity of OS data; key catalysts are Q1/2026 secondary endpoint readout and 2H/2026 cohort expansion readouts.

Trade implications: Tactical direct play is a size‑controlled long in CMPX (2–3% portfolio) ahead of the Q1 readout with phased entries (33% now, 33% after Feb directional hint, remainder 1–2 weeks pre‑readout). Hedge sector beta via a pair trade long CMPX vs short XBI at 0.5x notional; for convexity, buy a Jun‑2026 call spread (buy ATM, sell ~50% OTM) sized 0.5–1% notional and fund it with a smaller short call leg to cap cost; set a 30% stop or protective put if cash runway under 12 months.

Contrarian angles: The market may over‑price early response significance — 3/15 is noisy and historically many bispecifics regress in expansion; conversely, a positive PFS with immature OS can still spark >2x M&A bids, which the market might be underestimating. Watch for unintended consequences: a marginal PFS benefit without OS could force costly confirmatory trials and dilution, so calibrate position size and triggers (cash runway <12 months or safety signal) to avoid binary downside.

Key Decisions for Investors

• Establish a phased long position in CMPX equal to 2–3% of portfolio: 33% now, 33% after any positive interim safety/efficacy signal in Feb 2026, remainder 1–2 weeks before Q1/2026 PFS/OS readout; set a hard 30% stop-loss or buy protective puts if cash runway drops below 12 months.
• Buy a Jun‑2026 call spread on CMPX (buy ATM, sell ~50% OTM) sized to 0.5–1% of portfolio to capture the Q1 readout upside while capping premium, and consider pairing with a small 6‑month 30% OTM put as downside insurance funded by the short leg.
• Execute a relative‑value hedge: long CMPX vs short SPDR S&P Biotech ETF (XBI) at a 1:0.5 notional ratio to neutralize sector volatility; adjust hedge ratio after any clear readout direction.
• If within the next 60 days CMPX discloses impending dilution, regulatory hold, or a safety signal, reduce exposure to zero and reassess; conversely, if Q1/2026 PFS and interim OS trends are positive, scale to 4–5% and initiate outreach for potential M&A/partnering arbitrage opportunities.